NMS Group announces today that its board of directors has accepted the resignation of Ying Shao as CEO, effective October 1, 2020. The Board has contextually appointed as CEO Dr. Nanding Zhao.
Dr. Nanding Zhao, PhD and MBA, is an executive leader of drug discovery and development with an in-depth scientific knowledge and broad global business through 20 years of managing multi-disciplinary teams and multinational projects.
“This was a difficult decision that I reached after much reflection. It has been a privilege working with the best team in the business. I am proud of all we have accomplished together. I want to thank the team and the Board for their support. NMS Group has transformed over the years and is in a strong position both financially and competitively in the marketplace. It is on the speed track to a bright future!” said Shao.
Andrea Agazzi, Chairman of the Board of NMS Group: “On behalf of the board, we thank Dr. Shao for his service and many achievements during his tenure as CEO. His energy and dedication in transforming the Group to become more innovation-driven and more cultural-diverse are much appreciated by all staff and the Board. Please join me in wishing him the absolute best in all his future plans and endeavors. Now is the time to welcome Dr. Nanding Zhao and to work closely with him to boost our growth and achieve the goals that the Shareholders and all the employees expect.”